Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease-Reference-Cited by-同舟云学术

Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease

Published:2022-04-25 Issue:7 Volume:24 Page:1360-1369
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Parker Victoria E. R.¹^ORCID,Hoang Thuong²,Schlichthaar Heike³,Gibb Fraser W.⁴,Wenzel Barbara⁵,Posch Maximillian G.⁶,Rose Ludger⁷,Chang Yi‐Ting⁸,Petrone Marcella⁹,Hansen Lars⁸,Ambery Philip¹⁰^ORCID,Jermutus Lutz¹,Heerspink Hiddo J. L.¹¹^ORCID,McCrimmon Rory J.¹²^ORCID

Affiliation:

1. Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Cambridge UK

2. GW Pharmaceuticals Cambridge UK

3. Study Center, SMO.MD GmbH Magdeburg Germany

4. Royal Infirmary of Edinburgh Edinburgh UK

5. APEX GmbH Munich Germany

6. Charite Research Organisation GmbH Berlin Germany

7. Zentrum fur Diabetes Münster Germany

8. Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D AstraZeneca Gaithersburg MD USA

9. Clinical Pharmacology and Safety Sciences AstraZeneca Cambridge UK

10. Late Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden

11. Department of Clinical Pharmacy and Pharmacology University of Groningen Groningen The Netherlands

12. School of Medicine, Ninewells Hospital University of Dundee Dundee UK

Funder

AstraZeneca Pharma Poland

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14712

Reference43 articles.

1. Epidemiology of Diabetic Kidney Disease

2. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists

3. Obesity and Kidney Disease

4. Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus

5. Diabetic kidney disease: world wide difference of prevalence and risk factors;Gheith O;J Nephropharmacol,2016

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article;Indian Journal of Endocrinology and Metabolism;2024-09-04

2. Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach;CPT: Pharmacometrics & Systems Pharmacology;2024-07-23

3. Transforming obesity: The advancement of multi-receptor drugs;Cell;2024-07

4. Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future;Biomedicines;2024-06-21

5. Intra-islet α-cell Gs signaling promotes glucagon release;Nature Communications;2024-06-15